Ticarcillin

In response to the clinical treatment needs of multidrug-resistant Gram-negative bacterial infections, semi-synthetic penicillin antibiotics have always been an important medication option. Ticarcillin is a broad-spectrum anti-pseudomonas penicillin that exerts a bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides, and has strong antibacterial activity against Gram-negative bacteria such as *Pseudomonas aeruginosa*, *Escherichia coli*, and Proteus. It is often formulated into a compound preparation with clavulanic acid in clinical practice, for the treatment of sepsis, respiratory tract infections, biliary tract infections, urinary system infections and skin and soft tissue infections caused by susceptible bacteria, and is especially suitable for the treatment of *Pseudomonas aeruginosa* infections in immunocompromised patients.

The global market size of ticarcillin-related preparations is approximately USD 280 million. In recent years, driven by the rising demand for drug-resistant bacteria prevention and control and the expansion of the primary-level anti-infective drug market, the compound annual growth rate has remained at around 3.2%. In the domestic market, the ticarcillin and clavulanate potassium compound preparation has been included in the National Medical Insurance Catalog, and its clinical usage has increased steadily after centralized procurement. At present, the supply side is dominated by generic drugs, with local enterprises accounting for more than 70% of the market share, and the demand for active pharmaceutical ingredients (APIs) continues to grow along with the expansion of preparation production capacity.

The original research enterprise of ticarcillin is SmithKline Beecham (now GlaxoSmithKline), and the trade name of its original research compound preparation is "Timentin". The core compound patent expired globally in 1986. The commonly used dosage form of the original research product is ticarcillin sodium and clavulanate potassium for injection, with mainstream specifications of ticarcillin 3g/clavulanic acid 0.1g and ticarcillin 1.5g/clavulanic acid 0.05g, which has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. At present, the ticarcillin APIs of multiple domestic enterprises have obtained Grade A status through CDE registration, and the corresponding generic preparations have also been approved for marketing and supplied for clinical use. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for ticarcillin API. Most products are in stock, and orders placed before 16:00 can be shipped on the same day. All products comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully meet the demand for impurity reference standards in the process of API R&D, quality research and production.